Appeals court imposes restrictions on abortion pill, but drug will stay on the market for now

Appeals court imposes restrictions on abortion pill, but drug will stay on the market for now


A container holding boxes of Mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women’s Clinic in Carbondale, Illinois, April 20, 2023.

Evelyn Hockstein | Reuters

A federal appeals court on Wednesday imposed restrictions on the abortion pill mifepristone, though the ruling will not have an immediate impact.

The order by the U.S. 5th Circuit Court of Appeals is almost certain to be appealed to the Supreme Court. Justice Samuel Alito in April preemptively paused any ruling from the appeals court pending a petition for the high court to take the case.

If the Supreme Court does not take the case, the restrictions will go into effect.

The court battle over mifepristone comes more than a year after the Supreme Court abolished federal abortion rights by overturning the landmark 1973 Roe v. Wade ruling.

Mifepristone, used in combination with another drug called misoprostol, is the most common method to terminate a pregnancy in the U.S.

A panel of three judges at the 5th Circuit heard arguments May 17 from lawyers representing the Food and Drug Administration, mifepristone distributor Danco Laboratories, and a group of anti-abortion doctors called the Alliance for Hippocratic Medicine.

The judges were all appointed by Republican presidents. Judges James Ho and Cory Wilson were appointed by Donald Trump. Judge Jennifer Elrod was appointed by George W. Bush.

The FDA and Danco argued that the lawsuit seeking to pull mifepristone from the U.S. market is unprecedented, has no basis in science and will jeopardize women’s health.

The panel of judges pushed back hard on those arguments.

The judges questioned whether allowing women to receive mifepristone by mail without having to see a doctor would result in more patients seeking emergency care. Ho pushed back on the FDA and Danco’s characterization of the case as unprecedented.

“I don’t understand this theme — the FDA can do no wrong. That is basically the narrative you all are putting forth — nobody should ever question the FDA,” Ho said during Wednesday’s hearing.

“We are allowed to look at the FDA just like we are allowed to look at any agency, that’s the role of the courts,” Ho said. 

This is breaking news. Please check back for updates.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More